logo
Share SHARE
FONT-SIZE Plus   Neg

CHMP Adopts Negative Opinion On KYNAMROTM - Quick Facts

Genzyme, a Sanofi company (SNY: Quote), and Isis Pharmaceuticals Inc. (ISIS: Quote), announced the Committee for Medicinal Products for Human Use, or CHMP, of the European Medicines Agency has adopted a negative opinion for its marketing authorization application for KYNAMROTM for the treatment of patients with Homozygous Familial Hypercholesterolaemia. Genzyme plans to request a re-examination of the CHMP Opinion.

An application for KYNAMRO is currently under review by the U.S. FDA.

by RTT Staff Writer

For comments and feedback: editorial@rttnews.com

Business News

Editors Pick
Fiat Chrysler Automobiles NV (FCAU) is recalling nearly 26 thousand Chrysler 200s to fix a transmission issue that may prevent the vehicle from shifting into "park." Chrysler said that certain 2015-model year Chrysler 200 vehicles with V6 engines were affected. Chrysler blamed "inconsistent assembly... Gap reported an increase in fourth-quarter profit, as same store sales climbed 11 percent at its Old Navy brand, partly offset by currency impact. Earnings for the quarter topped Wall Street estimates by a penny, while sales were in line with expectations. J.C. Penney Co. Inc. (JCP) Thursday reported a swing to loss in the fourth-quarter from a profit last year, reflecting the absence of benefits from hefty tax gains recorded last year, despite a higher-than-expected revenue growth. Shares of the struggling department store chain plunged a near 10 percent,...
comments powered by Disqus
Follow RTT